Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.

Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92. doi: 10.1016/j.bmcl.2008.06.052. Epub 2008 Jun 27.

3.

Bone morphogenetic protein receptors and signal transduction.

Miyazono K, Kamiya Y, Morikawa M.

J Biochem. 2010 Jan;147(1):35-51. doi: 10.1093/jb/mvp148. Epub 2009 Sep 17. Review.

PMID:
19762341
4.

BMP signaling balances murine myeloid potential through SMAD-independent p38MAPK and NOTCH pathways.

Cook BD, Evans T.

Blood. 2014 Jul 17;124(3):393-402. doi: 10.1182/blood-2014-02-556993. Epub 2014 Jun 3.

5.

Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells.

Boergermann JH, Kopf J, Yu PB, Knaus P.

Int J Biochem Cell Biol. 2010 Nov;42(11):1802-7. doi: 10.1016/j.biocel.2010.07.018. Epub 2010 Aug 5.

PMID:
20691279
6.

Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.

Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT.

Nat Chem Biol. 2008 Jan;4(1):33-41. Epub 2007 Nov 18.

7.

Development of an ALK2-biased BMP type I receptor kinase inhibitor.

Mohedas AH, Xing X, Armstrong KA, Bullock AN, Cuny GD, Yu PB.

ACS Chem Biol. 2013;8(6):1291-302. doi: 10.1021/cb300655w. Epub 2013 Apr 30.

8.

Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.

Gillespie P, Goodnow RA Jr, Saha G, Bose G, Moulik K, Zwingelstein C, Myers M, Conde-Knape K, Pietranico-Cole S, So SS.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):949-53. doi: 10.1016/j.bmcl.2013.12.063. Epub 2013 Dec 24.

PMID:
24412066
9.

Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.

Garulli C, Kalogris C, Pietrella L, Bartolacci C, Andreani C, Falconi M, Marchini C, Amici A.

Cell Signal. 2014 Feb;26(2):352-62. doi: 10.1016/j.cellsig.2013.11.022. Epub 2013 Nov 23.

PMID:
24280125
10.

Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.

Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, Moorman A, Varani K, Gessi S, Merighi S, Borea PA.

J Med Chem. 2003 Mar 27;46(7):1229-41.

PMID:
12646033
11.

The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target.

Peng J, Yoshioka Y, Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Kharma B, Murakami R, Abiko K, Murphy SK, Konishi I.

Mol Carcinog. 2016 Apr;55(4):335-45. doi: 10.1002/mc.22283. Epub 2015 Feb 7.

PMID:
25663289
12.

In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.

Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, Hopkins CR, Lindsley CW, Hong CC.

ACS Chem Biol. 2010 Feb 19;5(2):245-53. doi: 10.1021/cb9002865.

13.

Application of small organic molecules reveals cooperative TGFβ and BMP regulation of mesothelial cell behaviors.

Cross EE, Thomason RT, Martinez M, Hopkins CR, Hong CC, Bader DM.

ACS Chem Biol. 2011 Sep 16;6(9):952-61. doi: 10.1021/cb200205z. Epub 2011 Jul 20.

14.

The specificities of small molecule inhibitors of the TGFß and BMP pathways.

Vogt J, Traynor R, Sapkota GP.

Cell Signal. 2011 Nov;23(11):1831-42. doi: 10.1016/j.cellsig.2011.06.019. Epub 2011 Jun 29.

PMID:
21740966
15.

Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.

Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY.

J Med Chem. 2013 Feb 28;56(4):1641-55. doi: 10.1021/jm301537p. Epub 2013 Feb 19.

PMID:
23362959
16.

Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation.

Yoshioka Y, Ono M, Osaki M, Konishi I, Sakaguchi S.

Eur J Immunol. 2012 Mar;42(3):749-59. doi: 10.1002/eji.201141702. Epub 2011 Dec 20.

17.

Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.

Ducray R, Ballard P, Barlaam BC, Hickinson MD, Kettle JG, Ogilvie DJ, Trigwell CB.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):959-62. doi: 10.1016/j.bmcl.2007.12.035. Epub 2007 Dec 23.

PMID:
18182285
18.

A new class of small molecule inhibitor of BMP signaling.

Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, Hill CS, Bullock AN.

PLoS One. 2013 Apr 30;8(4):e62721. doi: 10.1371/journal.pone.0062721. Print 2013.

19.

Synthesis and biological evaluation of pyrazolo[4,3-d]pyrimidine analogues.

Yuan L, Song C, Li C, Li Y, Dong L, Yin S.

Eur J Med Chem. 2013 Sep;67:152-7. doi: 10.1016/j.ejmech.2013.05.019. Epub 2013 May 24.

PMID:
23851116
20.

Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.

Ren L, Laird ER, Buckmelter AJ, Dinkel V, Gloor SL, Grina J, Newhouse B, Rasor K, Hastings G, Gradl SN, Rudolph J.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1165-8. doi: 10.1016/j.bmcl.2011.11.092. Epub 2011 Nov 30.

PMID:
22196124

Supplemental Content

Support Center